Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab for Early Residual Disease in Pediatric B-ALL
NCT06607419Phase 3Recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- May 2024
- Primary completion
- May 2025
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of blinatumomab in B-cell acute lymphoblastic leukemia (B-ALL), sponsored by Shanghai Jiao Tong University School of Medicine. Started May 2024; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
B-cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06607419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06607419.